Modulation of nuclear factor-κB-mediated pro-inflammatory response is associated with exogenous administration of bone marrow-derived mesenchymal stem cells for treatment of experimental colitis

Molecular Medicine Reports

Volumn 11, Issue 4, 2015, Pages 2741-2748

  Zuo, Dongmei ^a   Tang, Qing ^a   Fan, Heng ^a   Shou, Zhexing ^a   Liu, Xingxing ^a   Cao, Dan ^a   Zou, Zhou ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Bone marrow mesenchymal stem cells; Inflammatory bowel disease; Nuclear factor B; Tumor necrosis factor

Indexed keywords

NUCLEOPROTEIN; TRANSCRIPTION FACTOR RELA; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR ALPHA; AUTACOID; CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW DERIVED MESENCHYMAL STEM CELL; CELL ISOLATION; CELLULAR DISTRIBUTION; COLON MUCOSA; CONTROLLED STUDY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL COLITIS; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GOBLET CELL; HISTOLOGY; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATORY CELL; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STEM CELL CULTURE; TRANSLATION REGULATION; WESTERN BLOTTING; ANIMAL; BLOOD; CHEMICALLY INDUCED; COLITIS; DISEASE MODEL; GENETICS; IMMUNOPHENOTYPING; INTESTINE MUCOSA; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; METABOLISM; PATHOLOGY; PHENOTYPE;

RATTUS;

ANIMALS; COLITIS; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION; IMMUNOPHENOTYPING; INFLAMMATION MEDIATORS; INTESTINAL MUCOSA; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; NF-KAPPA B; PHENOTYPE; RATS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84921368647     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.3038     Document Type: Article

References (41)

1. Schirbel A and Fiocchi C: Inflammatory bowel disease: Established and evolving considerations on its etiopathogenesis and therapy. J Dig Dis 11: 266-276, 2010.
2. Baumgart DC and Carding SR: Inflammatory bowel disease: cause and immunobiology. Lancet 369: 1627-1640, 2007.
3. Hisamatsu T, Kanai T, Mikami Y, et al: Immune aspects of the pathogenesis of inflammatory bowel disease. Pharmacol Ther 137: 283-297, 2013.
4. Muzes G, Molnár B, Tulassay Z and Sipos F: Changes of the cytokine profile in inflammatory bowel diseases. World J Gastroenterol 18: 5848-5861, 2012.
5. Xavier RJ and Podolsky DK: Unravelling the pathogenesis of inflammatory bowel disease. Nature 448: 427-434, 2007.
6. de Zoeten E and Mamula P: What are the guidelines for using biologics in pediatric patients? Inflamm Bowel Dis 14 (Suppl 2): S259-S261, 2008.
7. Taba Taba Vakili S, Taher M and Ebrahimi Daryani N: Update on the management of ulcerative colitis. Acta Med Iran 50: 363-372, 2012.
8. Parekkadan B and Milwid JM: Mesenchymal stem cells as therapeutics. Annu Rev Biomed Eng 12: 87-117, 2010.
9. Meyerrose T, Olson S, Pontow S, et al: Mesenchymal stem cells for the sustained in vivo delivery of bioactive factors. Adv Drug Deliv Rev 62: 1167-1174, 2010.
10. Le Blanc K, Tammik C, Rosendahl K, Zetterberg E and Ringdén O: HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol 31: 890-896, 2003.
11. Le Blanc K, Tammik L, Sundberg B, Haynesworth SE and Ringdén O: Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol 57: 11-20, 2003.
12. Dalal J, Gandy K and Domen J: Role of mesenchymal stem cell therapy in Crohn's disease. Pediatr Res 71: 445-451, 2012.
13. Ringdén O, Uzunel M, Rasmusson I, et al: Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 81: 1390-1397, 2006.
14. Sun S, Guo Z, Xiao X, et al: Isolation of mouse marrow mesenchymal progenitors by a novel and reliable method. Stem Cells 21: 527-535, 20 03.
15. Morris GP, Beck PL, Herridge MS, et al: Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology 96: 795-803, 1989.
16. Davaatseren M, Hwang JT, Park JH, et al: Poly-γ-glutamic acid attenuates angiogenesis and inflammation in experimental colitis. Mediators Inflamm 2013: 982383, 2013.
17. González R, Rodríguez S, Romay C, et al: Anti-inflammatory activity of phycocyanin extract in acetic acid-induced colitis in rats. Parmacol Res 39: 55-59, 1999.
18. Guo Y, Su L, Wu J, et al: Assessment of the green fluorescence protein labeling methods for tracking implanted mesenchymal stem cells. Cytotechnology 64: 391-401, 2012.
19. Yi T and Song SU: Immunomodulatory properties of mesenchymal stem cells and their therapeutic applications. Arch Pharm Res 35: 213-221, 2012.
20. Uccelli A, Moretta L and Pistoia V: Mesenchymal stem cells in health and disease. Nat Rev Immunol 8: 726-736, 2008.
21. Tolar J, Le Blanc K, Keating A and Blazar BR: Concise review: hitting the right spot with mesenchymal stromal cells. Stem Cells 28: 1446-1455, 2010.
22. Krampera M, Cosmi L, Angeli R, et al: Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 24: 386-398, 2006.
23. Tanaka F, Tominaga K, Ochi M, et al: Exogenous administration of mesenchymal stem cells ameliorates dextran sulfate sodium-induced colitis via anti-inflammatory action in damaged tissue in rats. Life Sci 83: 771-779, 2008.
24. Cooper HS, Murthy SN, Shah RS and Sedergran DJ: Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest 69: 238-249, 1993.
25. Idriss HT and Naismith JH: TNF alpha and the TNF receptor superfamily: structure-function relationship(s). Microsc Res Tech 50: 184-195, 2000.
26. Locksley RM, Killeen N and Lenardo MJ: The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 104: 487-501, 2001.
27. Smith CA, Farrah T and Goodwin RG: The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell 76: 959-962, 1994.
28. Ogata H and Hibi T: Cytokine and anti-cytokine therapies for inflammatory bowel disease. Curr Pharm Des 9: 1107-1113, 2003.
29. Zheng L, Fisher G, Miller RE, et al: Induction of apoptosis in mature T cells by tumour necrosis factor. Nature 377: 348-351, 1995.
30. Noti M, Corazza N, Mueller C, Berger B and Brunner T: TNF suppresses acute intestinal inflammation by inducing local glucocorticoid synthesis. J Exp Med 207: 1057-1066, 2010.
31. Olson TS, Reuter BK, Scott KG, et al: The primary defect in experimental ileitis originates from a nonhematopoietic source. J Exp Med 203: 541-552, 2006.
32. Reimund JM, Wittersheim C, Dumont S, et al: Mucosal inflammatory cytokine production by intestinal biopsies in patients with ulcerative colitis and Crohn's disease. J Clin Immunol 16: 144-150, 1996.
33. Armuzzi A, Lionetti P, Blandizzi C, Caporali R, et al: Anti-TNF agents as therapeutic choice in immune-mediated inflammatory diseases: focus on adalimumab. Int J Immunopathol Pharmacol 27 (1 Suppl): 11-32, 2014.
34. Chen FE and Ghosh G: Regulation of DNA binding by Rel/NF-kappaB transcription factors: structural views. Oncogene 18: 6845-6852, 1999.
35. Barnes PJ and Karin M: Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 336: 1066-1071, 1997.
36. DiDonato JA, Hayakawa M, Rothwarf DM, Zandi E and Karin M: A cytokine-responsive IkappaB kinase that activates the transcription factor NF-kappaB. Nature 388: 548-554, 1997.
37. Schmitz ML, Bacher S and Kracht M: I kappa B-independent control of NF-kappa B activity by modulatory phosphorylations. Trends Biochem Sci 26: 186-190, 2001.
38. Pizarro TT and Cominelli F: Cytokine therapy for Crohn's disease: advances in translational research. Annu Rev Med 58:433-444, 2007.
39. Elson CO, Cong Y and Weaver CT: Monoclonal anti-interleukin 23 reverses active colitis in a T cell-mediated model in mice. Gastroenterol 132: 2359-2370, 2007.
40. Atreya R, Mudter J, Finotto S, et al: Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. Nat Med 6: 583-588, 2000.
41. Suenaert P, Bulteel V, Lemmens L, et al: Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease. Am J Gastroenterol 97: 2000-2004, 2002.